ProfileGDS5678 / 1418227_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 34% 33% 34% 51% 33% 33% 32% 29% 34% 34% 33% 32% 33% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8067134
GSM967853U87-EV human glioblastoma xenograft - Control 22.7593233
GSM967854U87-EV human glioblastoma xenograft - Control 32.7810234
GSM967855U87-EV human glioblastoma xenograft - Control 43.1917951
GSM967856U87-EV human glioblastoma xenograft - Control 52.6929433
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8183333
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7852532
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6419429
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7528934
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7698634
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7452633
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7007332
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.763633
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5547859